{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:13:35Z","timestamp":1771877615301,"version":"3.50.1"},"reference-count":10,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,23]]},"DOI":"10.1182\/blood.2023021954","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T16:31:01Z","timestamp":1700757061000},"page":"1761-1763","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Functional cure reported in CLL"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"21","key":"2023112316305349700_bib1","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2023112316305349700_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2023112316305349700_bib3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023112316305349700_bib4","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","article-title":"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"12","key":"2023112316305349700_bib5","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1038\/s41375-021-01280-8","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations","volume":"35","author":"Jain","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2023112316305349700_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood.2020008164","article-title":"A\u00a0fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial","volume":"137","author":"Michallet","year":"2021","journal-title":"Blood"},{"issue":"22","key":"2023112316305349700_bib7","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023112316305349700_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for\u00a0chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023112316305349700_bib9","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023112316305349700_bib10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/21\/1761\/2089978\/blood_bld-2023-021954-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/21\/1761\/2089978\/blood_bld-2023-021954-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T16:31:07Z","timestamp":1700757067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/21\/1761\/498725\/Functional-cure-reported-in-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":10,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021954","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}